Please use this identifier to cite or link to this item: https://doi.org/10.1002/prca.201100050
DC FieldValue
dc.titleS100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis
dc.contributor.authorWu, W.
dc.contributor.authorJuan, W.C.
dc.contributor.authorLiang, C.R.M.Y.
dc.contributor.authorYeoh, K.G.
dc.contributor.authorSo, J.
dc.contributor.authorChung, M.M.
dc.date.accessioned2014-12-12T07:13:25Z
dc.date.available2014-12-12T07:13:25Z
dc.date.issued2012-04
dc.identifier.citationWu, W., Juan, W.C., Liang, C.R.M.Y., Yeoh, K.G., So, J., Chung, M.M. (2012-04). S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics - Clinical Applications 6 (3-4) : 152-162. ScholarBank@NUS Repository. https://doi.org/10.1002/prca.201100050
dc.identifier.issn18628346
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/115278
dc.description.abstractPurpose: We have mined the gastric fluid proteome for potential gastric cancer (GC) biomarkers that may enhance disease detection and facilitate prognostic monitoring. Experimental design: In biomarker discovery, a total of 12 patient gastric fluid samples (stages I, III, IV and gastritis) were analysed by 2DE for expression changes that correlated with GC status or disease progression. Gastric fluid proteins showing differential expression with GC were identified by MALDI-TOF/TOF MS as putative biomarkers. Levels of these potential biomarker candidates were independently validated by Western blotting in further 60 gastritis and GC patients. A targeted approach that recruits biomarker candidates for panel consideration was adopted to test if two or more biomarkers in combination improved diagnostic power. Results: From the 15 differentially regulated proteins identified, expression levels of S100A9, GIF and AAT in the gastric fluid clearly correlated with GC status. S100A9/AAT (AUC = 0.81) and S100A9/GIF (AUC = 0.92) were revealed as promising biomarker pairs for early GC diagnosis and disease monitoring, respectively. Conclusion and clinical relevance: Early diagnosis, accurate staging and constant disease monitoring remain the prerequisites for effective treatment against GC. As current biomarkers like CA19-9 and carcinoembryonic antigen (CEA) lack sensitivity and specificity, there is a pressing need for novel GC detection and monitoring methods. To this end, S100A9, GIF and AAT from the gastric fluid may significantly augment existing methods of GC detection and monitoring, and eliminate the need for invasive tissue biopsies. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1002/prca.201100050
dc.sourceScopus
dc.subjectAAT
dc.subjectCombinatorial biomarkers
dc.subjectGIF
dc.subjectS100A9
dc.typeArticle
dc.contributor.departmentMECHANOBIOLOGY INSTITUTE
dc.description.doi10.1002/prca.201100050
dc.description.sourcetitleProteomics - Clinical Applications
dc.description.volume6
dc.description.issue3-4
dc.description.page152-162
dc.identifier.isiut000303194800002
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

21
checked on Aug 23, 2019

WEB OF SCIENCETM
Citations

18
checked on Aug 23, 2019

Page view(s)

87
checked on Aug 16, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.